Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX -1.61%28 3-Year EBITDA Growth Rate is 71.40% as of Mar. 2026, which is 760% above its 10-year median of 8.30. GuruFocus rates EVAX with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Evaxion AS ranks better than 93.63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 71.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 51.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Evaxion AS was 71.40% per year. The lowest was -63.10% per year. And the median was 8.30% per year.
Evaxion AS (NAS:EVAX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Evaxion AS 3-Year EBITDA Growth Rate Related Terms
EVAX vs CRVO, ALGS, TVRD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Evaxion AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Evaxion AS's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 71.40% mean?
Evaxion AS (EVAX) has a 3-Year EBITDA Growth Rate of 71.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Evaxion AS and its competitors. This is 760% above median its historical median of 8.30. According to the industry distribution chart, Evaxion AS ranks #72 out of 1131 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Evaxion AS's 3-Year EBITDA Growth Rate too high?
Evaxion AS's current 3-Year EBITDA Growth Rate of 71.40% is 760% above median its 10-year median of 8.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Evaxion AS's value of 71.40% is 379.2% above this industry median. Based on the distribution chart, Evaxion AS ranks #72 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Evaxion AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's 3-Year EBITDA Growth Rate compare to CRVO and ALGS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #72 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Evaxion AS in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Evaxion AS's value of 71.40% is 379.2% above this benchmark. While the company's 10-year median is 8.30 vs. the industry median of 14.90, Evaxion AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evaxion AS's current 3-Year EBITDA Growth Rate of 71.40% is 379.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Evaxion AS and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current 3-Year EBITDA Growth Rate is 71.40%, which is 760% above median its own 10-year median of 8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current 3-Year EBITDA Growth Rate of 71.40%. The current 3-Year EBITDA Growth Rate is 71.40%, which is 760% above median its 10-year median of 8.30 and 379.2% above the Biotechnology industry median of 14.90. Evaxion AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Evaxion AS (EVAX), the current 3-Year EBITDA Growth Rate is 71.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
28GF Score
Get the complete analysis for EVAX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
